Core Insights - The pharmaceutical commercial sector experienced a decline of 1.0% on October 24, with Jianfa Zhixin leading the drop [1] - The Shanghai Composite Index closed at 3950.31, up 0.71%, while the Shenzhen Component Index closed at 13289.18, up 2.02% [1] Market Performance - The following companies showed varied performance in the pharmaceutical commercial sector: - Huaren Health (301408) closed at 13.17, up 0.46% with a trading volume of 44,500 shares and a turnover of 58.44 million yuan [1] - Runda Medical (603108) closed at 14.76, up 0.20% with a trading volume of 64,400 shares and a turnover of 95.39 million yuan [1] - Jianfa Zhixin (301584) led the decline, closing at 35.66, down 4.14% with a trading volume of 341,300 shares and a turnover of 1.289 billion yuan [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 259 million yuan from institutional investors, while retail investors contributed a net inflow of 248 million yuan [2] - The following companies had notable capital flows: - Shanghai Pharmaceutical (601607) had a net inflow of 6.9169 million yuan from institutional investors [3] - Baiyang Pharmaceutical (301015) experienced a net inflow of 6.5687 million yuan from institutional investors [3] - Runda Medical (603108) had a net inflow of 3.8868 million yuan from retail investors [3]

证券日报网讯 10月23日晚间，南京医药发布公告称，截至2025年10月22日，公司完成回购，公司已通 过集中竞价交易方式累计回购公司股份1，799.9852万股，占公司2025年10月22日总股本130，893.0265 万股的1.38%。 （文章来源：证券日报） ...

格隆汇10月23日丨南京医药(600713.SH)公布，截至2025年10月22日，公司完成回购，公司已通过集中 竞价交易方式累计回购公司股份1,799.9852万股，占公司2025年10月22日总股本的1.38%，回购最高价 格为5.22元/股，回购最低价格为4.69元/股，使用资金总额为8,892.21万元（不含交易费用）。 ...

证券代码：600713 证券简称：南京医药 公告编号：ls2025-131 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/3/15 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 月 2025 3 3 | 14 | 日~2026 | 年 | 日 14 | | 预计回购金额 | 7,000万元~13,158万元 | | | | | | 回购价格上限 | 7.31元/股 | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | □用于转换公司可转债 | | | | | | | □为维护公司价值及股东权益 | | | | | | 实际回购股数 | 1,799.9852万股 | | | | | | 实际回购股数占总股本比例 | 1.38% | ...

证券代码：600713 证券简称：南京医药 编号：ls2025-133 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 2025 年度第四期超短期融资券兑付公告 托管在银行间市场清算所股份有限公司的债券，其兑付资金由发行人在规定时 间之前划付至银行间市场清算所股份有限公司指定的收款账户后，由银行间市场清 算所股份有限公司在兑付日划付至债券持有人指定的银行账户。债券兑付日如遇法 定节假日，则划付资金的时间相应顺延。债券持有人资金汇划路径变更，应在兑付 前将新的资金汇划路径及时通知银行间市场清算所股份有限公司。因债券持有人资 金汇划路径变更未及时通知银行间市场清算所股份有限公司而不能及时收到资金的， 发行人及银行间市场清算所股份有限公司不承担由此产生的任何损失。 三、相关机构联系人和联系方式 （一）发 行 人：南京医药股份有限公司 联 系 人：周昊鹏 联系方式：025-84552638 （二）存续期管理机构：上海浦东发展银行股份有限公司 联 系 人：张文杰 联系方式：025-68777248 （三）登记托管机构：银行间市场清算所股份有限公司 联系部门：运营部 联 系 人：谢晨燕、陈龚荣 联系方式 ...

证券代码：600713 证券简称：南京医药 编号：ls2025-132 一、本期债券基本情况 1 二、兑付相关事宜 托管在银行间市场清算所股份有限公司的债券，其兑付资金由发行人在规定时 间之前划付至银行间市场清算所股份有限公司指定的收款账户后，由银行间市场清 算所股份有限公司在兑付日划付至债券持有人指定的银行账户。债券兑付日如遇法 定节假日，则划付资金的时间相应顺延。债券持有人资金汇划路径变更，应在兑付 前将新的资金汇划路径及时通知银行间市场清算所股份有限公司。因债券持有人资 金汇划路径变更未及时通知银行间市场清算所股份有限公司而不能及时收到资金的， 发行人及银行间市场清算所股份有限公司不承担由此产生的任何损失。 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 2025 年度第一期超短期融资券兑付公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为保证南京医药股份有限公司 2025 年度第一期超短期融资券（债券简称：25 南京医药 SCP001，债券代码：012580364 ）兑付工作的顺利进行，现将有关 ...

南京医药公告，公司已完成回购1799.99万股，占总股本的1.38%，实际回购金额为8892.21万元，价格 区间为4.69元/股至5.22元/股。此次回购用于实施2025年限制性股票激励计划。公司首次披露回购方案 日期为2025年3月15日，预计回购金额在7000万元至1.32亿元之间。回购股份所用资金来源为公司自有 资金或自筹资金。 ...

南京医药公告称，将兑付2025年度第四期超短期融资券（25南京医药SCP004）本息。该债券发行金额5 亿元，起息日为2025年5月22日，期限180天，本计息期债项利率1.54%。本息兑付日为2025年11月18日 （遇法定节假日顺延），本期应偿付本息金额50379.73万元（以最终兑付为准）。主承销商为上海浦东 发展银行和南京银行。 ...

Policy Developments - The State Administration for Market Regulation and the National Medical Products Administration conducted legislative research on the Medical Device Management Law, emphasizing the importance of scientific, democratic, and legal legislation to enhance the quality of laws and promote implementation [2] Drug and Device Approvals - East China Pharmaceutical's subsidiary received a drug registration certificate for Remabizine injection, which is used in conjunction with MediBeacon's device to assess patients' kidney function [4] - Kelun Pharmaceutical's subsidiary obtained approval for its targeted antibody-drug conjugate, Boduocizumab, for treating HER2-positive breast cancer patients who have received prior anti-HER2 therapies, showing significant improvement in progression-free survival [5] Financial Reports - Wowo Pharmaceutical reported a net profit increase of 179.34% year-on-year for the first three quarters, with revenues of 625 million yuan [7] - Pianzaihuang's third-quarter net profit decreased by 28.82% year-on-year, attributed to reduced sales in the pharmaceutical manufacturing sector and declining gross margins [8] Capital Market Activities - Weigao Blood Products is planning to acquire 100% of Shandong Weigao Purui Pharmaceutical Packaging Co., leading to a stock suspension for up to 10 trading days [11] - Hansoh Pharmaceutical entered a licensing agreement with Roche, potentially earning up to $1.45 billion in milestone payments for the development of HS-20110, a targeted antibody-drug conjugate for colorectal cancer [12][13] - Maipu Medical plans to acquire 100% of Guangzhou Yijie Medical Technology for 335 million yuan and raise additional funds [15] Industry Developments - Sanofi announced the launch of its insulin raw material project in Beijing, with a total investment of 1 billion euros, expected to be completed by 2032 [18]

Policy Developments - The State Administration for Market Regulation and the National Medical Products Administration conducted legislative research on the draft Medical Device Management Law, emphasizing the importance of scientific, democratic, and legal legislation to enhance the quality of laws and promote implementation [1] Drug and Device Approvals - East China Pharmaceutical's subsidiary received a drug registration certificate for Remabizine injection, which is used in conjunction with MediBeacon's device to assess patients' glomerular filtration rate [2] - Kelun Pharmaceutical's subsidiary obtained approval for its ADC product, Botuzumab, for treating HER2-positive breast cancer, showing significant improvement in progression-free survival compared to T-DM1 [3] Financial Reports - WoHua Pharmaceutical reported a net profit increase of 179.34% year-on-year for the first three quarters, with revenue of 625 million yuan [4] - Pianzihuang's third-quarter net profit decreased by 28.82%, with revenue down 26.28% year-on-year, attributed to reduced sales in the pharmaceutical manufacturing sector [5] Capital Market Activities - Weigao Blood Products is planning to acquire 100% of Shandong Weigao Puri Pharmaceutical Packaging Co., leading to a stock suspension for up to 10 trading days [7] - Hansoh Pharmaceutical entered a licensing agreement with Roche, potentially earning up to $1.45 billion in milestone payments for the development of HS-20110, a targeted ADC for colorectal cancer [8] Industry Developments - Sanofi announced the launch of its insulin raw material project in Beijing, with a total investment of 1 billion euros, expected to be completed by 2032 [12]